Citations

Clear

2096 citation(s) found for "Ho, Vincent".

B47-35 A Silent Complication: Rare Case of Inhaled Tobramycin Associated Ototoxicity in Patient With Preserved Renal Function
Singh, A, Singh, A, Phadke, R, Surana, A, Jena, A, Bhattacharya, R, Martin, K B, SURANA, ARIHANT, Martin, Kevin Braun

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1260 Get It

Abstract Introduction Aminoglycoside antibiotics are well known to cause cochlear and vestibular toxicity when used systemically. Inhaled tobramycin was developed to reduce systemic exposure and is considered safer with only rare reports of ototoxicity have been reported in patients with renal dysfunction. We describe a case of bilateral sensorineural hearing loss (SNHL) and tinnitus associated with inhaled tobramycin in a patient without renal impairment, emphasizing that even inhaled formulations can induce significant auditory toxicity in susceptible individuals. Case A 85 year old woman with Sjogren’s related interstitial lung disease and bronchiectasis who was chronically colonized by Pseudomonas aeruginosa was treated with inhaled tobramycin for recurrent infections. She had normal renal function and no prior aminoglycoside exposure. After approximately three months of inhaled therapy, she noted progressive bilateral hearing decline and high pitched tinnitus without vertigo or otalgia. Physical examination revealed clear ear canals and intact tympanic membranes. Baseline audiometry one year ago had demonstrated mild to moderately-severe bilateral SNHL. Repeat testing after tobramycin exposure showed worsening thresholds and reduced word recognition bilaterally. MRI of the brain and internal auditory canals was unremarkable. Serum creatinine remained normal throughout treatment. Inhaled tobramycin was discontinued, after which hearing loss stabilized. No further progression was observed on follow-up audiometry. Discussion Although systemic absorption from inhaled tobramycin is typically low, elderly and low-body-weight patients may accumulate sufficient serum levels to cause cochlear injury. Mechanisms include reactive oxygen species mediated hair cell toxicity and possible genetic susceptibility involving the mitochondrial 12S rRNA mutation. Prior reports of vestibulotoxicity and cochleotoxicity from inhaled tobramycin primarily involved patients with renal dysfunction, however, this case report demonstrates that toxicity can occur despite preserved renal function. Clinicians should maintain vigilance for otologic symptoms in patients receiving inhaled aminoglycosides. Baseline and periodic audiometric monitoring should be incorporated into chronic treatment protocols. This abstract is funded by: None
D21-16 Muc1, Muc4 and Ceacam5 Expression Are Elevated in Severe Asthma and Correlate With the Degree of Obstruction and Prospective Exacerbations
Gauthier, M C, Kale, S L, Vincent, A M, Ross, M A, Mehta, I, Calderon, M, Ramonell, R P, Christenson, S A, Woodruff, P G, Castro, M, Jarjour, N N, Sumino, K, Denlinger, L C, Gaston, B, Bleecker, E R, Meyers, D A, Moore, W C, Israel, E, Levy, B D, Mauger, D T, Erzurum, S C, Nee, T J, Ray, P, Croix, C M St, Wenzel, S E, Das, J, Ray, A, Vincent, Augusta, Ross, M, Calderon, Michael Joseph , Ramonell, Richard Paul , Sumino, K., Denlinger, Loren C. , Meyers, Deborah A. , Israel, Elliot , Levy, Bruce David , Nee, Taylor J., Croix, Claudette M. St. , Wenzel, Sally E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.660 Get It

Abstract Rationale Type-1 inflammation in asthma leads to significant airway level changes independent of Type-2 inflammation and may underlie the severity seen in combined Type1/2 high disease. As IFNs can cause airway epithelial injury and impaired repair, we applied a novel interpretable machine learning algorithm, SLIDE, to analyze the transcriptome of airway epithelial brushings of mild-moderate (MMA) and severe asthma (SA) participants in the Immune Mechanisms in Severe Asthma (IMSA) cohort to identify latent/hidden factors of disease that associate with disease severity. Methods The expression of genes identified by SLIDE as part of a co-expression program was assessed in the full IMSA cohort by severity and in an independent cohort of the NHLBI Severe Asthma Research Program (SARP). We also examined associations of these genes with clinical asthma outcomes in both cohorts. Results SLIDE identified aberrant increased expression of membrane-tethered mucin genes, MUC1 and MUC4. MUC1 appeared in each of 5 significant latent factors associated with greater severity and MUC4 in 2/5. Standard DGE analysis also identified the gene CEACAM5 as a predictor of severity. Pathway analysis of latent factor genes revealed airway keratinization which may contribute to airway remodeling and worsening obstruction over time. Expression of MUC1, MUC4, and CEACAM5 were increased in SA compared to HC in both the full IMSA and separate SARP cohorts (p < 0.001 for all genes in both cohorts). Expression in MMA was consistently lower than in SA in both cohorts, reaching significance in IMSA (p < 0.01) but not consistently in SARP (MUC1 p = 0.04, MUC4 p = 0.27, CEACAM5 p = 0.27). Protein analysis of endobronchial biopsies by immunofluorescence staining showed a trend towards increased MUC1 protein content with evidence of secretion. MUC1, MUC4 and CEACAM5 were negatively correlated with FEV1 % predicted in both cohorts (IMSA: MUC1 r=-0.47, p < 0.01, MUC4 r=-0.47, p < 0.01, CEACAM5 r=-0.62, p < 0.01; SARP: MUC1 r=-0.19, p = 0.05, MUC4 r=-0.29, p < 0.01, CEACAM5 r=-0.51, p < 0.01). All three genes positively correlated with prospective exacerbations in both cohorts (IMSA: MUC1 r = 0.345, p = 0.01, MUC4 r = 0.216, p = 0.08, CEACAM5 r = 0.368, p < 0.01; SARP: MUC1 r = 0.22, p = 0.02, MUC4 r = 0.32, p < 0.01, CEACAM5 r = 0.38, p < 0.01). Conclusions The expression of MUC1, MUC4 and CEACAM5 increased with asthma severity in the airway epithelium and correlated with both prospective exacerbations and obstruction. As pathway analysis of genes in the significant latent factors were associated with airway keratinization aberrant expression of these mucins (with known signaling functions) may contribute to maladaptive repair and airway remodeling that drives obstruction over time, contributing to worse asthma outcomes. This abstract is funded by: NIH
C55-32 Temporal Trends and Racial Disparities in ARDS Mortality Location in the United States (2003-2020)
Lim, A, Mee, X, Lim, G, Phang, C, Cho, T

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.203 Get It

Abstract Aim Acute respiratory distress syndrome (ARDS) is a life-threatening condition frequently managed in intensive care units, with high in-hospital mortality. Less is known about where mortality happens once care transitions beyond hospital. This study aimed to assess national trends in the location of ARDS-related deaths in the U.S. from 2003 to 2020 to evaluate racial and ethnic disparities in end-of-life settings. Methods A retrospective analysis was performed using Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) death certificate data from 2003 to 2020 for all decedents with ARDS (ICD-10 code J80) within the U.S. The proportion of deaths by location (medical facility, decedent’s home, hospice facility, nursing home/long-term care, and other/unknown) was calculated for each year. Linear regression was used to evaluate temporal trends in the proportion of deaths across the study period. Odds ratios (ORs) were calculated using 2 × 2 contingency tables to compare the likelihood of dying in a specific location (e.g., hospice facility, medical facility) between racial and ethnic groups. Results There were 29,028 ARDS deaths in the U.S. from 2003 to 2020. The majority (95.52%) of deaths occurred in medical facilities, with smaller proportions at nursing facilities (1.52%), home (1.50%), hospice (0.69%), other locations (0.33%), and unknown (0.43%). There were no significant changes in the proportions of deaths occurring in medical facilities, decedents’ homes, or nursing homes/long-term care facilities (P > .05 for all). However, the proportion of ARDS deaths occurring in hospitals increased significantly among Black (0.73% to 0.78% (P < .03)) and Asian/Pacific Islander patients (0.12% to 0.19% (P < .01)). Black patients had higher odds of dying in a medical facility compared to White patients (OR = 3.44). No ARDS decedents in the Asian or American Indian groups died outside a medical facility, yielding ORs that approached infinity for these groups. Conclusion The location of ARDS deaths in the U.S. remained largely constant from 2003 to 2020, with most patients dying in hospital settings. This highlights the severity of ARDS and its high in-hospital mortality, reflecting that intensive care is typically required for management. Despite advances in supportive therapies, the persistently high rate of in-hospital deaths suggests limited improvements in out-of-hospital transitions. This study also identified racial disparities. Black patients had higher odds of dying in medical facilities compared to White patients, suggesting inequities in access to home-based end-of-life care options. This abstract is funded by: None
Predictors of renal response in AL amyloidosis following anti‐plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype
Rees, Matthew J., Yohannan, Binoy, Geyer, Susan M. , Atallah‐Yunes, Suheil Albert , Toumeh, Nadia , Gertz, MA, Dispenzieri, Angela, Leung, Nelson , Hayman, Suzanne, Buadi, Francis, Dingli, David, Warsame, Rahma, Kapoor, Prashant , Kourelis, Taxiarchis, Gonsalves, Wilson, Kumar, Shaji, Gertz, Morie A. , Geyer, Susan , Gertz, Morie A , Cook, Joselle M , Rajkumar, S Vincent , Muchtar, E , Leung, Nelson , Atallah-Yunes, Albert , Rees, Matthew J. , Yohannan, Binoy, Dispenzieri, Angela , Hayman, S., Buadi, Francis K. , Cook, Joselle , Dingli, David , Warsame, Rahma , Binder, Moritz , Kourelis, Taxiarchis , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Kumar, Shaji , Muchtar, Eli

Mayo Clinic

British Journal of Haematology | May 11, 2026 | Volume: 209 | Issue: 1 | Pages: 149-159

10.1111/bjh.70542 | PMID 42108212 Get It

Summary Renal response (RenR) in light‐chain (AL) amyloidosis is associated with a lower risk of end‐stage kidney disease and improved survival. However, substantial variation exists in the time to and depth of RenR. We investigated variables associated with RenR in a retrospective study of newly diagnosed AL amyloidosis patients ( n = 350) assessable for RenR between 2010 and 2022. RenRs were recorded at 6, 12 and 24 months and best response. Deep RenR was defined as a ≥renal very good partial response (RenVGPR, >60% reduction in 24‐h proteinuria or ≤200 mg). Logistic regression and competing risk methods were used to examine variables associated with RenR. The median age was 64 years, and median follow‐up was 5.5 years. On multivariable logistic regression, obtaining ≥HemVGPR within 6 months, kappa isotype, high baseline difference between involved and uninvolved free light chains (dFLC ≥40 mg/dL), renal stage and autologous haematopoietic stem cell transplant (AHSCT) were significantly associated with deep RenR. Cumulative incidence rates for deep RenR, treating death or renal progression as a competing event, demonstrated that early HemR, first‐line AHSCT, lower renal stage and dFLC ≥40 mg/dL significantly increased the likelihood of deep RenR. Specific clonal plasma cell features, namely light‐chain isotype and baseline dFLC levels, independently influence the timing and depth of RenRs in AL amyloidosis following treatment, in addition to renal stage and HemR.
Ventricular conduction is a marker for arrhythmic risk in SCN5A- E1784K overlap sodium channel disease
Tanck, Michael W.T. , Wijeyeratne, Yanushi D. , Barc, Julien , Muir, A.J.L., Aiba, Takeshi , Bos, Martijn, Veltmann, Christian , Galvin, Joseph , Crotti, Lia , Ishikawa, Taisuke , Ohno, Seiko , Page, Stephen P, Denjoy, I, Tester, David J. , Muggenthaler, Martina, Takahashi, Kazuhiro , GOURRAUD, JEAN BAPTISTE, Haglund-Turnquist, Carla, Pedrazzini, Matteo , Alberio, Chiara , Petzer, Edward, Roden, Dan M. , Borggrefe, Martin , Ackerman, Michael J. , McKeown, Pascal , Behr, Elijah R. , Bos, J. Martijn , Bos, Johan M , Denjoy, Isabelle , Raju, Hariharan , Gourraud, Jean-Baptiste , Redon, Richard , Jacques Schott, Jean , Pedrazzini, Matteo , Alberio, Chiara , Dagradi, Federica , Papadakis, Michael , Sharma, Sanjay , Petzer, Edward , Roden, Dan M. , Horie, Minoru , Schwartz, Peter J. , Makita, Naomasa , Borggrefe, Martin , Shimizu, Wataru , Probst, Vincent , Behr, Elijah Raphael , Ishikawa, Taisuke , Crotti, Lia , Tanck, Michael , Barc, Julien , Aiba, Takeshi , Veltmann, Christian , Galvin, Joseph , Ohno, Seiko , Denjoy, Isabelle , Muggenthaler, Martina, Gourraud, Jean‐Baptiste , Redon, Richard , Schott, Jean‐Jacques , Haglund-Turnquist, Carla , Dagradi, Federica

Mayo Clinic

Europace | May 9, 2026 | Volume: 28 | Issue: 6 | Pages: No page available

10.1093/europace/euag113 | PMID 42114100 Get It

Abstract Aims SCN5A-E1784K (c.5350G>A) is the most common variant associated with the long QT (LQTS) and Brugada syndromes (BrS). It can manifest variably as LQTS, BrS, and/or conduction disorders. This presents a challenge for risk stratification. We aimed to describe clinical and ECG characteristics and identify risk markers that associate with arrhythmic events. Methods and results We undertook a retrospective observational multicentre study of a large cohort of 231 subjects with SCN5A-E1784K from Europe, USA, and Japan. Comprehensive demographic and clinical data, including initial presentation ECG and follow-up, were collected. ‘Lethal events’ were defined as sudden death, non-fatal cardiac arrest, and documented sustained VT or VF. ‘Cardiac events’ were defined as arrhythmic syncope plus any lethal events. Clinical characteristics and ECG parameters corrected for age were investigated for association with lethal and/or cardiac events. Fourteen (6%) subjects experienced a lethal event and 45 (19%) a cardiac event. PR interval and QRS duration were associated with lethal and cardiac events. In multivariable models, both PR interval and QRS duration were associated with lethal events, but only QRS duration was associated with cardiac events. Only age-corrected QRS (rQRS) was associated with lethal and cardiac event-free survival from birth after correction for multiple testing. Conclusion Ventricular myocardial conduction appears likely to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. This provides an important opportunity for the personalization of management and has the potential to guide preventative therapies.
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
Bahlis, Nizar J. , Facon, Thierry, San-Miguel, Jesus, Usmani, Saad Z., Dimopoulos, Meletios-Athanasios A., Moreau, Philippe, Manier, Salomon , NS, Raje, Orlowski, Robert Z. , Goldschmidt, H, Hulin, Cyrille, Weisel, K, Leleu, Xavier, Plesner, Torben , Jakubowiak, Andrzej J, Cook, Gordon, Quach, H, Venner, Christopher P., Cavo, M, Ngo, Mai, Bolyard, Kasey, Carson, R, Borgsten, Fredrik, Mateos, María‐Victoria , Kumar, Shaji , Miguel, Jesús F. San , Bahlis, Nizar Jacques , San-Miguel, Jesus , Zweegman, Sonja , Perrot, Aurore , Manier, Salomon , Orlowski, Robert Z. , Goldschmidt, Hartmut , Mohty, Mohamad , Leleu, Xavier , Cook, Gordon , Quach, Hang , Mateos, María-Victoria , Kumar, Shaji K , Facon, Thierry T.F. , Usmani, Saad Z. , Dimopoulos, Meletios A , Moreau, Philippe , Chari, Ajai , Goldschmidt, Hartmut , Basu, Supratik , Hulin, Cyrille , Weisel, Katja C , Mohty, Mohamad , Leleu, Xavier , Jakubowiak, Andrzej , Cook, Gordon , Quach, Hang , Cavo, M., Carson, Robin

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: 10 | Issue: 13 | Pages: 4541-4550

10.1182/bloodadvances.2025019323 | PMID 42085642 Get It

Abstract Both the phase 3 MAIA and ALCYONE studies demonstrated significant survival benefit with the addition of daratumumab to standard-of-care Rd (Revlimid [lenalidomide] and dexamethasone; D-Rd) or to VMP (Velcade [bortezomib], melphalan, and prednisone; D-VMP), respectively, vs Rd or VMP alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Patients with NDMM are highly susceptible to infection; therefore, gaining a greater understanding of infection incidence may help to mitigate future risk. We conducted a pooled analysis of infection incidence, timing, and management strategies from MAIA and ALCYONE. The median (range) age of the pooled population was 72 (40-93) years. Incidence was higher with D-Rd/D-VMP vs Rd/VMP for grade 3/4 (36.9% vs 22.4%) and grade 5 (3.0% vs 1.5%) infections; however, exposure-adjusted incidence rates were generally comparable between groups. Any-grade infections led to the discontinuation of study treatment in ∼2% of patients across treatment groups. Of the timing intervals explored, the highest incidence of grade 3/4 infection occurred within the first 6-month interval of study treatment initiation in both groups. Median time to the first onset of grade 3/4 infections (per Kaplan-Meier estimates) was 83.3 months and not estimable in the D-Rd/D-VMP and Rd/VMP groups, respectively. Although the rates of D-Rd/D-VMP treatment discontinuation due to infection remained low in MAIA and ALCYONE, clinicians should remain vigilant about infections throughout treatment and follow local guidelines and International Myeloma Working Group recommendations to minimize the risk of infection. These trials were registered at www.ClinicalTrials.gov as NCT02252172 (MAIA) and NCT02195479 (ALCYONE).
Deep mutational scan of the pore of the cold-sensing TRPM8 channel
Pike, Averi , Le, Vincent , Turner, Ashlin, Galván, Carmen, Vazhavilla, Ashley, Salinas, Richard, Bramble, Matt, Wylie, D K, Podnar, Jessica, Hoskins, Ian, Cenik, Can , Jara-Oseguera, Andrés , Pike, Averi L. , Le, Vincent , Turner, Ashlin , Wylie, Dennis C., Podnar, Jessica W.

Mayo Clinic

No container title available | May 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.28.721489 | PMID 42094376 Get It

Abstract Members of the Transient Receptor Potential (TRP) family of ion channels have a nearly ubiquitous role in human physiology, tuning cell signaling to remarkably diverse physical and chemical stimuli. Although there is extensive structural data on TRP channels, a systematic and unbiased interrogation of structure-function relations in these proteins is required to fully elucidate their mechanisms of function. By focusing on a critical pore region of the TRPM8 channel, which is the main detector of cold and cooling agents in sensory neurons, we show how deep mutational scanning can be used in combination with the available structural data to understand how TRP channels respond to stimuli. We define a novel mechanism whereby the extracellular pore loop, which has only been resolved in structures representing desensitized states of the channel, plays an essential role in the response of TRPM8 to menthol or cold by coordinating the movement of the S6 helices that line and gate the pore, and the ion-selectivity filter that binds permeant cations. Moreover, our screen reveals sequence determinants along the S6 helices that explain how their architecture sustains gating and, together, provide strong support for a structural mechanism of TRPM8 pore opening in response to menthol and cold.
Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus
Meletti, Stefano, Hanin, Aurelie, Bedin, Roberta , Burani, Margherita , Taruffi, Lisa , Urbano, Teresa, d’Achille, Fabio, Malerba, Mara, Basha, Maysaa M., Eschbach, Krista, Farias-Moeller, Raquel, Gerard, Elisabeth E., Gofton, Teneille, Gopaul, Margaret T., Haider, Hiba A. , Hantus, Stephen , Herman, Susan, Kang, Peter, Kandula, Padmaja , Taraschenko, Olga , Wainwright, Mark, Zhou, Daniel J., Lattanzi, Simona, Navarro, Vincent, Hirsch, Lawrence J., Meletti, Stefano , Haider, Hiba A , Hanin, Aurélie , Giovannini, Giada , Orlandi, Niccolò , Urbano, Teresa , Malerba, Mara, Basha, Maysaa , Foreman, Brandon , Farias‐Moeller, Raquel , Gaspard, Nicolas , Gofton, Teneille , Gopaul, Margaret , Day, Gregory S. , Steriade, Claude , Struck, Aaron F. , Wainwright, Mark S. , Yoo, Ji Yeoun , Lattanzi, Simona , Navarro, Vincent , Hirsch, Lawrence J.

Mayo Clinic

JAMA Neurology | April 27, 2026 | Volume: 83 | Issue: 6 | Pages: 563

10.1001/jamaneurol.2026.0865 | PMID 42043830 Get It

Importance Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. Objective To quantify acute brain injury in patients with cryptogenic NORSE (cNORSE), etiology-defined status epilepticus (eSE), and chronic epilepsy. Design, Setting, and Participants This was an international cross-sectional study conducted between 2013 and 2025. Patients were enrolled at 36 hospitals in the US, 2 in Canada, and 1 in Italy, France, and Belgium. Patients with cNORSE and eSE for which biological samples were obtained during ongoing seizure activity were enrolled in the study. Comparison groups without status epilepticus comprised individuals with chronic epilepsy and healthy participants. None were excluded. Exposures Neurofilament light chain (NfL) and S100-beta (S100B) protein concentrations in serum and cerebrospinal fluid (CSF). Main Outcomes and Measures Degree of neuronal and glial damage, indexed by NfL and S100B levels, and their association with short-term functional outcomes. Results A total of 78 patients with cNORSE (mean [95% CI] age, 37 [30-41] years; 44 female [56%]) and 2 independent cohorts of 211 patients (mean [95% CI] age, 69 [66-71] years; 128 female [61%]) and 73 patients (mean [95% CI] age, 56 [45-65] years; 39 male [53%]) with eSE were included. NfL concentrations were markedly elevated in cNORSE—approximately 10-fold higher in CSF and 4-fold higher in serum—compared with the eSE cohorts (CSF: median [IQR], 6408 [1503-22 963] pg/mL compared with 694 [219-2389] pg/mL; serum: median [IQR], 231 [99-855] pg/mL compared with 55 [20-135] pg/mL; P <.001). Serum NfL levels were nearly 20-fold higher in cNORSE than in the cohort with epilepsy and in healthy controls (median [IQR], 11 [7-19 ] and 7 [5-14 ] pg/mL, respectively). Serum and CSF NfL levels were strongly correlated (Spearman ρ = 0.75; P < .001) and rose sharply between week 1 (median [IQR], 101 [51-137] pg/mL), week 2 (median [IQR], 197 [117-324] pg/mL), and week 3 (median [IQR], 598 [163-1000] pg/mL) after onset ( P < .001). In contrast, S100B concentrations did not differ between groups and showed no consistent temporal pattern. NfL discriminated cNORSE from eSE (area under the receiver operating characteristic curve [AUROC], 0.79; 95% CI, 0.68-0.90) and from cohorts without status epilepticus (AUROC, 0.99; 95% CI, 0.78-1.00). Higher serum NfL was independently associated with poor functional outcome at discharge (Glasgow Outcome Scale extended score, 1-4; odds ratio, 1.01; 95% CI, 1.00-1.03; P = .03). Conclusions and Relevance Results of this cross-sectional study suggest that acute neuroaxonal injury, as reflected by elevated NfL levels, was substantially greater in cNORSE than in the cohorts with eSE and in controls without status epilepticus. The rapid early rise in NfL highlights a narrow therapeutic window, emphasizing the need for prompt, effective, and potentially neuroprotective interventions in cNORSE.
Personalized and Precision Oncology (PPO) via Cancer Pathology related Modeling and IT-Assisted Clinical Practice to Prevent, to Treat and to Get Cured Cancer and Its Complications: A Role of Precision Cancer Pathology in the Era of PPO
Suchkov, Sergey, Thilly, William G., Murphy, Shawn, Smith, David A. , Abe, Hiroyuki, Duffy, Michael Joe, Cheng, R Holland, Suchkov, Sergey, Murphy, Shawn, Abe, Hiroyuki, Duffy, Michael Joe, Cheng, R Holland

Mayo Clinic

Journal of Cancer Research Reviews & Reports | April 24, 2026 | Volume: 7 | Issue: 2 | Pages: 1

10.47363/jcrr/2025(7)210 Get It

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, Personalized and Precision Medicine (PPM). To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the recogni-tion of biomarkers and thus the targets to secure the grand future of drug design and drug dis-covery.Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications to provide more tai-lored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost-effective use of the latest health care resources including diagnostic (companion ones or theranostics), preventive and therapeutic (targeted molecular and cellular) etc.Meanwhile, along with the impact of genomics and bioinformatics, pathology is the central specialty of PPM-related resources. Coupled with IT, the upgraded tools are ever more efficient and robust within clinical cancer settings. The latest algorithms may be able to identify and vali-date patterns which humans are not capable of quantifying easily, such as slight differences in textures or morphologies. In this sense, the impact of pathology allows a modular approach, as its various aspects are under development in several areas of PPM.Among the above-mentioned medical specialists involved in PPM, the pathologists play an im-portant and key role in the implementation and development of PPM-driven resources that are in the center of decision of many therapeutic choices. Recent advances in systems biology have tremendously affected the practice of precision pathology, gradually transforming it from a morphology-based into a precise molecular-based discipline. The enormous development of precision pathology research (integrating molecular OMICS and digital approaches) has raised great expectations concerning its impact on PPM aiming to custom-ize medical practice with a focus on the individual, based on the use of molecular tests, identifi-cation of genomic biomarkers, and development of targeted drugs.The precision pathology process introduces a new paradigm in pathology by leveraging digital imaging and IT technologies, and provides significant advancements in accuracy, efficiency, and collaboration. Among the latest innovations the precision pathology supported by digital tools, would dictate the implementation of high-resolution imaging, image analysis tools and integra-tion with molecular OMICS data. Integration of the approaches and resources will provide a true challenge for the future, requiring collaboration between oncologists, pathologists, biodesigners and bioengineers and remaining a challenge to precision cancer practice and profiled bioindustry.The latter requires precision pathologists highly trained in pre-analytic processes, tumor area mi-crodissection for tumor cell enrichment, methodology analysis and results. The in-depth study of molecular alterations in patients allows optimizing molecular diagnosis and selecting candidates for receive novel treatments against specific molecular targets. These patients would benefit from multidisciplinary approach and learning. In this sense, molecular diagnostics has a long tradition in pathology, especially in clinical one, where various OMICS-analyses of cancers are incorpo-rated into diagnostic and decision-making algorithms to secure a way where the pathologists con-tinue to play an essential role in developing and implementing molecular profiling tests in practice and communicate the results and their relevance with cancer practitioners.Cancer pathology is the central specialty of personalized and precision oncology (PPO). Meanwhile, the combination of comprehensive biobanking and the next wave of theranostic pathology technologies provides a natural, externally visible infrastructure that now allows pa-thology as a discipline – to engage directly with the biotechnology and pharma sector. We’re at an exciting junction in precision cancer pathology’s growth as a medical specialty, and pathology-driven biobanking is becoming both central to our core expertise and, even more importantly, a powerful enabler for many of the most promising growth areas of our discipline: PPM healthcare, clinical trials and drug development, theranostics, and functional assessment and monitoring of disease. In the context of these changes and challenges, the precision cancer pathology can play a fundamental role in both PPO-guided clinical practice and biodesign-driven cancer research.
The Impact of Endoscopic Ultrasound and Multidisciplinary Team Evaluation on the Management of Pancreatic Cystic Lesions
Altayar, Osama , Hoegger, Mark J. , Chu, Linda, Zaheer, Atif , Zandieh, Ghazal , Kushnir, Vladimir , Lang, Gabriel , Goggins, Michael, Hawkins, William, Khan, Adeel , Burns, William, Lafaro, Kelly, Lim, Kian‐Huat, Pederson, Katrina, Das, Koushik K. , Altayar, Osama , Genere, Juan Reyes , Khan, Adeel , Das, Koushik , Dbouk, Mohamad H. , Genere, Juan Reyes , Rengarajan, Arvind , Mellnick, Vincent M. , Shetty, Anup S. , Goggins, Michael , Lafaro, Kelly J. , Lim, Kian-Huat , Afghani, Elham

Mayo Clinic

United European Gastroenterology Journal | April 23, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/ueg2.70212 | PMID 42023483 Get It

ABSTRACT Background Retrospective evaluations of multidisciplinary team (MDT) review of pancreatic cystic lesions (PCL) demonstrate improved PCL management. Endoscopic ultrasound (EUS) evaluates PCL for worrisome features; however, its influence on MDT is unclear and may be attenuated by anchoring/confirmation bias. We aimed to evaluate the impact of EUS and the overall performance of MDT evaluation of PCL. Methods Four mock MDT sessions at two institutions were presented imaging from 40 consecutive PCL cases (20 “high‐risk” with advanced neoplasia, 20 “low‐risk” with pathologic low‐grade dysplasia or ≥ 3 years of non‐progression on surveillance), with and without upfront EUS/FNA (cytology, CEA, Amylase), in a randomized, crossover design. Group 1 adjudicated without EUS, Group 2 adjudicated with EUS, and Group 3 adjudicated with EUS after initially adjudicating without it. Results The cohort included branch‐duct ( n = 20), mixed type ( n = 6), and main duct ( n = 4) IPMN, MCN ( n = 5), and non‐mucinous PCL ( n = 5). Group 2 (EUS) correctly identified mucinous PCL with 97% sensitivity and 70% specificity, significantly higher than Group 1 (No EUS) (Sensitivity 91%, Specificity 20%; p = 0.04). Group 3 (Unblinded to EUS) performed significantly worse in mucinous PCL identification compared with Group 2, indicating cognitive bias (Sensitivity 97%, Specificity 10% ( p = 0.0003)). Group 2 correctly identified high‐risk PCL that required surgical intervention with 85% sensitivity and 85% specificity, significantly higher than Group 1 (Sensitivity 60%, Specificity 75%; p = 0.0016) and Group 3 (Sensitivity 73%, Specificity 80%, p = 0.0485). Conclusion While susceptible to cognitive bias, EUS significantly improves MDT assessment of PCL. MDT establishes a high bar for iterative additions of biomarkers to PCL analysis.